Skip to content
The Policy VaultThe Policy Vault

Thalomid (thalidomide)Medica

Medulloblastoma

Initial criteria

  • age < 18 years
  • Patient has recurrent or progressive disease
  • Medication is used as part of MEMMAT regimen (thalidomide, celecoxib, fenofibrate, oral etoposide, cyclophosphamide, bevacizumab, intraventricular etoposide)

Approval duration

1 year